Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bionutrics buys Kirk

This article was originally published in The Tan Sheet

Executive Summary

Phoenix-based supplement and product development firm purchases OTC and generic drug manufacturer Kirk Pharmaceuticals and affiliate Andapharm for $12 mil. in cash and debt, Bionutrics announces July 25. Bionutrics CEO Ronald Lane says the acquisition adds Kirk's "manufacturing and development resources for new OTC drugs employing Bionutrics' proprietary drug technology." Bionutrics is shifting its primary focus from dietary supplement evolvE toward conducting clinical trials for new proprietary supplements "developed to address lipid metabolism and assist in the maintenance of normal cholesterol" slated for launch later this later, according to a June SEC filing...

You may also be interested in...

OTC omeprazole

Synovics Pharmaceuticals announces March 15 it has entered into a binding letter of intent for exclusive, worldwide rights to the development and commercialization of an OTC omeprazole. Contract processor Fluid Air will deliver the product to Phoenix-based Synovics' subsidiary Kirk Pharmaceuticals. Fluid Air's DuraGran technology will allow Synovics to avoid patent infringement, the firm says. Synovics, formerly known as Bionutrics, bought Kirk in July 2005 (1"The Tan Sheet," Aug. 1, 2005, In Brief). Synovics plans to submit an ANDA in the second half of 2007. Perrigo said in a February analyst call it expects to launch an omeprazole product in November 2008 (2"The Tan Sheet," Feb. 5, 2007, p. 5). Under a licensing agreement, Schering-Plough hopes to bring Santarus' immediate release omeprazole product Zegerid to the market as well (3"The Tan Sheet" Nov. 27, 2006, In Brief)...

QUOTED. 3 March 2021. Greg Dadika.

Medtech Insight spoke to attorney Greg Dadika about mass tort litigation, including industry trends, how to find the right law firm, and when it’s the right time to settle a suit. See what Dadika, an attorney at the law firm Greenberg Traurig LLP, said about it here.

AstraZeneca/FibroGen’s Roxadustat Comparison To ESAs In Anemia May By Clarified At FDA Advisory Cmte.

Payers would welcome any additional clarity provided by advisory panel review, given the perception, expressed in a recent ICER report, that the evidence is insufficient to determine whether the new drug is safer or more effective than erythropoiesis-stimulating agents.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts